Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379220 | 0.86 | ALDH1A1 (0.31) | — | |
| SCHEMBL781122 | 0.82 | ADRB2 (0.36) | — | |
| SCHEMBL780879 | 0.73 | — | — | |
| SCHEMBL3517051 | 0.72 | ADRA1A (0.36) | SMN1; SMN2ACHE | |
| SCHEMBL779538 | 0.69 | F7 (0.37) | LPAR2LPAR3LPAR1 | |
| SCHEMBL27972128 | 0.68 | CYP4F2 (0.36) | SMN1; SMN2KDM4EACHE | |
| SCHEMBL2436695 | 0.68 | GAA (0.33) | SMN1; SMN2KDM4EACHE | |
| SCHEMBL305414 | 0.66 | GAA (0.36) | SMN1; SMN2KDM4EACHE | |
| SCHEMBL28716838 | 0.66 | — | — | |
| SCHEMBL4412214 | 0.66 | GAA (0.36) | SMN1; SMN2KDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | disclosed |
| US-20110224340-A1 | Method for Producing Mono-Vinylfunctionalized Dialkylphosphinic Acids, Salts and Esters Thereof, and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-15 | — | — | US | disclosed |
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213059-A1 | Method for Producing Mono-Carboxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by means of Vinylenes-Nitriles and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, HACL2, ACSL3 | SMN1; SMN2 4252/4885KDM4E 4042/4885LPAR2 217/4885 |
| US-20110213059-A1 | Method for Producing Mono-Carboxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by means of Vinylenes-Nitriles and Use Thereof | ACSL3, ACSL1, ACSL6 | SMN1; SMN2 4174/4885KDM4E 3797/4885LPAR2 575/4885 |
| US-20110224340-A1 | Method for Producing Mono-Vinylfunctionalized Dialkylphosphinic Acids, Salts and Esters Thereof, and the Use Thereof | ACSL1, ACSL3, HACL2 | SMN1; SMN2 4300/4885KDM4E 3410/4885LPAR2 331/4885 |
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | ACSL3, ACSL6, ACSL1 | SMN1; SMN2 3968/4885KDM4E 2594/4885LPAR2 438/4885 |
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, ACSL1, ACSL3 | SMN1; SMN2 4484/4885KDM4E 4040/4885LPAR2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.